Table 2 Studies identified by the systematic review and eligible for inclusion in the NMA

Buse[61]

US

30

377

GLP-1

1) exenatide 5 μg BID (125);

Unchanged from baseline SU^b,c

At least the maximally effective dose of a SU^c as monotherapy for ≥3 months before screening

2) exenatide 10 μg BID (129);

3) placebo BID (123)

Garber[62]

US, Sweden, Finland, Argentina, Lithuania

24

515

DPP-4

1) vildagliptin 50 mg QD (170);

Glimepiride 4 mg QD, reduced to 2 mg QD if hypoglycaemia occurred

≥7.5 mg glyburide or glipizide QD, or ≥2 mg glimepiride or equivalent, treated for >3 months with stable dose for ≥4 weeks before screening, switched to glimepiride 4 mg QD for 4 weeks prior to baseline

2) vildagliptin 100 mg QD (169);

3) placebo QD (176)

Hermansen[63]

Multi-country

24

212^d

DPP-4

1) sitagliptin 100 mg QD (106);

Stable dose of glimepiride (4 mg – 8 mg QD)

A stable dose of glimepiride 4 – 8 mg QD for ≥10 weeks + 2 week run-in

2) placebo QD (106)

Lewin[64]

US, Argentina, India, Japan, Hungary, Poland, Russia

18

245

DPP-4

1) linagliptin 5 mg QD (161);

Unchanged from baseline SU^b,c

Stable SU^c dose of ≥ half the maximum dose for 10 weeks (or documented maximum tolerated dose for ≥12 weeks) + 2 week run-in

2) placebo QD (84)

Strojek[31]

Czech Republic, Hungary, Poland, Ukraine, Republic of Korea, Philippines, Thailand

24

597

SGLT2

1) dapagliflozin 2.5 mg QD (154);

Glimepiride 4 mg QD, reduced to 2 mg QD or discontinued if hypoglycaemia occurred

Stable SU^c dose of ≥ half the maximum dose for 8 weeks. Continued on or switched to glimepiride 4 mg/day during an 8 week run-in

2) dapagliflozin 5 mg QD (145);

3) dapagliflozin 10 mg QD (151);

4) placebo QD (146)